13.10.2024, 862 Zeichen

Marinomed: Marinomed Biotech AG has published clinical data from the phase II dose-finding clinical trial evaluating the efficacy of Tacrosolv eye drops in patients with allergic rhinoconjunctivitis in the peer-reviewed “Clinical Ophthalmology” journal. The placebo-controlled allergen challenge trial assessed the efficacy and safety of two different doses of Tacrosolv. The results show that the higher dose of Tacrosolv eye drops (0.005% Tacrolimus) significantly reduced ocular symptoms of allergic conjunctivitis, and surprisingly, also the associated nasal allergy symptoms. Remarkably, these results were achieved with a dose that is 20-fold lower than that of the only Tacrolimus eye drop product currently on the market.
Marinomed Biotech: weekly performance: 0.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (08/10/2024)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1203: ATX mit AT&S stärker, Marinomed-Vermutung, diese 7 Börsepeople tippten Spanien und wir Kalajdzic

Bildnachweis

Aktien auf dem Radar:Frequentis, AT&S, Zumtobel, Austriacard Holdings AG, Polytec Group, SBO, OMV, EuroTeleSites AG, Rosenbauer, Semperit, Erste Group, Marinomed Biotech, Wienerberger, Wolftank-Adisa, Wiener Privatbank, SW Umwelttechnik, BKS Bank Stamm, Amag, Bawag, CPI Europe AG, Österreichische Post, Telekom Austria, UBM.

---